Table 2 Clinical and laboratory parameters at CRRT initiation
Overall (n = 110) | 14-day survival | p-value | ||
|---|---|---|---|---|
Survivor, n = 76 | Non-survivor, n = 34 | |||
SBP, mmHg | 115.5 ± 24.7 | 118.0 ± 25.9 | 110.0 ± 21.1 | 0.12 |
DBP, mmHg | 67.6 ± 14.5 | 68.5 ± 15.4 | 65.6 ± 12.1 | 0.33 |
MAP, mmHg | 83.6 ± 14.9 | 85.0 ± 15.2 | 80.4 ± 14.0 | 0.13 |
pulse rate, /min | 97.0 ± 23.4 | 94.5 ± 24.4 | 102.5 ± 20.2 | 0.10 |
Vasopressor use, n (%) | 58.0 (52.7) | 34 (44.7) | 24 (70.6) | 0.01 |
Prescription of CRRT | ||||
Duration of CRRT, day | 6.1 ± 6.7 | 7.0 ± 7.5 | 4.1 ± 3.8 | 0.01 |
Fluid removal (ml/hr) | 31.5 ± 47.6 | 37.2 ± 49.9 | 18.5 ± 39.8 | 0.04 |
Dialysate flow rate, mL/h | 1020.0 ± 206.8 | 1036.2 ± 171.8 | 983.8 ± 268.8 | 0.22 |
Replacement flow rate, mL/h | 1170.9 ± 894.8 | 1225.7 ± 1058.7 | 1048.5 ± 273.7 | 0.34 |
Blood flow rate, mL/min | 119.5 ± 30.5 | 120.7 ± 31.6 | 116.8 ± 28.1 | 0.54 |
Anticoagulation use, n (%) | 60.0 (54.5) | 48 (64) | 12 (35.3) | 0.01 |
Laboratory findings | ||||
Creatinine, mg/dL | 5.2 ± 2.2 | 5.22 ± 2.17 | 5.18 ± 2.27 | 0.94 |
eGFR, mL/min/1.73m2 | 13.3 ± 10.0 | 13.28 ± 10.78 | 13.19 ± 7.95 | 0.96 |
White blood cells, n/μL | 11.7 ± 7.5 | 11.31 ± 6.52 | 12.59 ± 9.51 | 0.41 |
Hemoglobin, g/dL | 9.2 ± 1.7 | 9.23 ± 1.59 | 9.03 ± 1.9 | 0.57 |
Platelets, × 103/μL | 143.8 ± 84.9 | 142.8 ± 84.16 | 145.91 ± 87.63 | 0.86 |
PT-INR | 2.2 ± 5.6 | 2.03 ± 5.76 | 2.61 ± 5.33 | 0.64 |
Total bilirubin, mg/dL | 1.0 ± 1.1 | 0.91 ± 1.03 | 1.13 ± 1.11 | 0.36 |
Aspartate aminotransferase, IU/L | 183.5 ± 918.1 | 168.33 ± 1024.15 | 217.56 ± 631.24 | 0.80 |
Alanine aminotransferase, IU/L | 99.1 ± 471.5 | 95.54 ± 545.4 | 106.79 ± 250.34 | 0.91 |
Lactic acid, mg/dL | 32.2 ± 39.5 | 26.1 ± 29.85 | 44.62 ± 52.88 | 0.13 |
Blood gas analysis | ||||
pH | 7.4 ± 0.1 | 7.37 ± 0.09 | 7.38 ± 0.11 | 0.50 |
base excess | -2.8 ± 6.3 | -2.74 ± 6.26 | -2.84 ± 6.54 | 0.94 |
PaO2, mmHg | 104.4 ± 57.9 | 105.21 ± 53.39 | 102.48 ± 68.16 | 0.82 |
PaCO2, mmHg | 42.0 ± 27.7 | 43.93 ± 32.49 | 37.4 ± 8.77 | 0.27 |